-
J. Edward Moreno
Posts
FDA clarifies stricter stance on GLP-1 compounding: Reuters
Hims, historically seen as one of the largest sellers of copycat GLP-1s, sunk on the news.
The FDA is expected to lift restrictions on certain peptides, the NYT reports
Peptides — a class of understudied and often injectable supplements — have boomed in popularity, with search interest for “peptides” surpassing “ozempic” this month.
Trump reportedly willing to end Iran war without reopening the Strait of Hormuz
Analysts at Signum Global told clients in a note that they find it “extremely unlikely” that Trump would end the war without at least trying…
Fermi falls after annual report shows steep losses, still no tenant
Fermi, which went public in October, is down about 80% since its IPO.
Fundrise’s venture fund falls amid concerns about valuation gap
The fund is still trading well above its net asset value, which was $18.26 per share as of March 2, according to its IPO documents.
The peptide gold rush: How impending deregulation could supercharge a shadow industry
Peptides, the gray-market supplements that have flooded Silicon Valley, may soon make their way into the mainstream. Who stands to benefit?
Fundrise’s venture fund extends rally, trading more than 2 dozen times above asset value
Fundrise Innovation Fund (VCX), a publicly traded venture fund that owns stakes in private companies like Anthropic, OpenAI, and SpaceX, is continuing to rally as…
Arm says its in-house AI chip will generate billions in revenue
Arm CEO Rene Haas said the new chip is expected to generate $15 billion in annual revenue by 2031.
Retail traders sold more stocks than they bought for the first time since 2023
Monday was the first day since November 2023 where retail investors flipped to selling.
Fundrise’s venture fund, which owns private tech giants like Anthropic and SpaceX, surges as retail investors pile in
The fund’s blockbuster public debut underscores how hungry retail investors are to get a piece of private companies.